摘要
目的观察长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床疗效,1年生存率和毒副反应。方法 67例晚期非小细胞肺癌患者随机分为对照组(33例)和治疗组(34例)。对照组采用GP方案治疗(吉西他滨+顺铂);治疗组则采用长春瑞滨联合顺铂治疗。治疗结束后观察两组治疗总有效率及毒副反应。结果治疗组总有效率为58.8%,对照组总有效率为45.5%,差异有显著性(P<0.05);治疗组1年生存率为47.1%,对照组1年生存率为30.3%,差异有显著性(P<0.05);两组患者毒副反应发生率无明显差异性(P>0.05)。结论长春瑞滨联合顺铂治疗晚期非小细胞肺癌可提高临床疗效和1年生存率,且毒副反应可耐受,是治疗晚期非小细胞肺癌的首选方案。
Objective To observe the clinical efficacy,1-year survival rate and toxicities reaction of vinorelbine combined with cisplatin in the treatment of advanced non-small cell lung cancer.Methods Sixty-seven patients with advanced non-small cell lung cancer were randomly divided into two groups： control group（33 cases） were treated with only GP regimen（Gemcitabine＋Cisplatin）,while treatment group（34 cases） were treated with combined therapy of vinorelbine and cisplatin.The total effective rate,survival rate of one year and toxicities reaction were observed after treatment.Results The total effective rate of treatment group was 58.8% and 45.5% in control group,with significant difference（P〈0.05）;The survival rate of one year in two groups was 47.1% and 30.3%,with significant difference（P〈0.05）;The toxicities reaction of two groups had no statistically significant difference（P〉0.05）.Conclusion The treatment of vinorelbine combined with cisplatin could improve the clinical efficacy and 1-year survival rate,and the toxicities reaction was mild and tolerable.It is a preferred regimen on treatment of advanced non-small cell lung cancer.
出处
《临床肺科杂志》
2011年第11期1729-1731,共3页
Journal of Clinical Pulmonary Medicine
关键词
长春瑞滨
顺铂
吉西他滨
非小细胞肺癌
vinorelbine
cisplatin
gemcitabine
Non-small cell lung cancer
